UK markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.2300+0.0100 (+0.45%)
As of 01:35PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 177.60M
Enterprise value 94.37M
Trailing P/E 13.66
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.78
Price/book (mrq)1.46
Enterprise value/revenue 2.09
Enterprise value/EBITDA -5.61

Trading information

Stock price history

Beta (5Y monthly) 0.42
52-week change 3-55.51%
S&P500 52-week change 3-13.51%
52-week high 35.3800
52-week low 31.9200
50-day moving average 32.1920
200-day moving average 32.7649

Share statistics

Avg vol (3-month) 312.81k
Avg vol (10-day) 34.9k
Shares outstanding 579.89M
Implied shares outstanding 6N/A
Float 852.85M
% held by insiders 10.00%
% held by institutions 11.19%
Shares short (14 Nov 2022) 4147.79k
Short ratio (14 Nov 2022) 48.49
Short % of float (14 Nov 2022) 4N/A
Short % of shares outstanding (14 Nov 2022) 40.18%
Shares short (prior month 13 Oct 2022) 4130.87k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin -39.99%
Operating margin (ttm)-32.98%

Management effectiveness

Return on assets (ttm)-4.30%
Return on equity (ttm)-17.31%

Income statement

Revenue (ttm)56.98M
Revenue per share (ttm)0.71
Quarterly revenue growth (yoy)242.50%
Gross profit (ttm)-22.3M
EBITDA -14.33M
Net income avi to common (ttm)-21.63M
Diluted EPS (ttm)-0.6940
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)123.35M
Total cash per share (mrq)1.54
Total debt (mrq)43.37M
Total debt/equity (mrq)37.28
Current ratio (mrq)2.34
Book value per share (mrq)1.46

Cash flow statement

Operating cash flow (ttm)-26.08M
Levered free cash flow (ttm)-40.59M